Possible Autoimmune Breakthrough With BCMA CAR T Therapy
It is well to be noted that the positive results from the first global study for chimeric antigen receptor (CAR)-antologous T cell- BCMA CAR...
NHSs BRCA Gene Testing Programme To Ascertain Cancer Risk
The BRCA gene testing initiative looks to identify individuals who carry genetic faults associated with an elevated risk of specific cancers, thereby enabling early...
Prescribe Fluoroquinolone Antibiotics As Last Resort – MHRA
It has been determined that fluoroquinolone antibiotics should only be prescribed in cases where no other antibiotics happen to be appropriate for use, as...
2024 Has A Lot Many Questions In Store For Pharma Companies
The advent of powerful new drugs in the case of obesity has gone on to reshape the pharma sector, thereby transforming Eli Lilly as...
CDMO-Biotech Ties Help Cut Business Risk In Drug Development
Biotech companies go on to face numerous challenges, particularly while in the clinical phase of drug development, in today's fast-paced industry. The astronomically high...
Cancer Research Boosts Small Molecule CDMO Market Expansion
The projected worth of the Global Small Molecule Innovator CDMO Market is anticipated to surpass $76.50 billion by 2031, displaying a compounded annual growth...
Breakthrough Cell & Gene Therapies To Transform Healthcare
Gene and cell therapies have the potential to revolutionize healthcare by reprogramming the immune system to treat diseases that are difficult to address with...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...